Russian Non-Interventional Study on Compliance of Venous Thromboembolism (VTE)

Bayer2,293 enrolled

Overview

This is a local, prospective, multicenter, non-interventional, observational study. Primary objective is to describe how in "real life" thromboprophylaxis is carried out after the discharge from a hospital in the patients who undergo elective knee and hip replacement and who receive Xarelto during hospitalization.

Study Type

OBSERVATIONAL

Enrollment

2,293

Conditions

Arthroplasty, Replacement, Hip Arthroplasty, Replacement, Knee

Interventions

Rivaroxaban (Xarelto, BAY59-7939)DRUG

The patients will be treated according to the routine practice. All the patients meeting the criteria of inclusion and exclusion to whom administration of Xarelto is indicated are fit for participation in this non-interventional study.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male and female patients ≥ 18 years old * Elective hip or knee replacement * Planned VTE prevention with Xarelto * Written informed consent * The decision for treatment type and duration is taken by the investigator and is made before inclusion into the study. Exclusion Criteria: * Contraindications for the use of Xarelto in accordance with the effective instruction * Any reasons of medical and non-medical character, which in the opinion of the physician can hamper participation of the patient in NIS, including a potentially low compliance, impossibility of making the final visit due to distant place of residence of the patient.

Locations (1)

Unnamed facility

Many Locations, Russia

Outcomes

Primary Outcomes

Real life out-patient thromboprophylaxis after arthroplasty: Share of patients who follow physician's prescriptions; true duration of out-patient thromboprophylaxis; duration of treatment interruptions; in case of switching - reasons, drug regimen.

Time frame: Not more than 8 weeks

Secondary Outcomes

Descriptive characteristics of prescription behaviour of orthopedists (VTE prevention recommended at discharge): continuation of rivaroxaban, switching to other products (name, dose, duration, efficacy control), mechanical prophylaxis, etc.

Time frame: Not more than 8 weeks

Adverse event characteristics (frequency, severity, relation to VTE prevention treatment, AE treatment, AE outcome)

Time frame: Not more than 8 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.